This is the first phase 1a/b study evaluating the safety and efficacy of MEK1/2 inhibitor binimetinib with c-MET inhibitor crizotinib, and was supported by preclinical data showing synergy between MEK1/2 and MET inhibition in KRASMT CRC models [20]. Here, MAP2K1 is linked to colorectal carcinoma.